For clinical trial sponsors, the changes go beyond approval pathways and start-up timelines. The amended framework also introduces important updates and clarifications for clinical trial safety reporting, annual safety reporting, reference safety information, non-investigational medicinal products and urgent safety measures.

For sponsors running new or ongoing UK clinical trials, this is a timely opportunity to review whether pharmacovigilance processes, study-level documentation, vendor responsibilities and escalation pathways remain aligned with the updated UK requirements.

 

Key pharmacovigilance areas sponsors should review

 

What has changed for clinical trial safety reporting?

The amended regulation supports a more streamlined and risk-proportionate UK clinical trial environment. However, it also reinforces the need for clear safety oversight throughout the study lifecycle.

For sponsors, the most important changes are not limited to individual reporting requirements. They also affect how clinical operations, medical monitoring, pharmacovigilance, regulatory affairs and study management teams work together.

1. SUSAR and DSUR reporting pathways

For UK CTIMPs, SUSARs and annual safety reports are now reported only to the MHRA, removing routine duplicate submission to UK Research Ethics Committees.

This may reduce administrative duplication, but it also increases the importance of strong internal tracking. Sponsors should ensure that MHRA submissions, acknowledgements, follow-up information and any missing acknowledgements are managed consistently and documented appropriately.

2. Follow-up safety reporting

Sponsors should review how follow-up safety information is identified, assessed and submitted.

Clear ownership is important. Study teams need to understand who is responsible for collecting follow-up information, who assesses it, who submits it, and how timelines are monitored.

3. DSUR preparation and RSI alignment

The DSUR process has been further clarified, including expectations around content, submission timing, signal management and the use of reference safety information.

This means sponsors should ensure that DSUR preparation is not treated as a standalone reporting activity. RSI strategy, Investigator Brochure updates, SAR re-assessment, signal management and global safety inputs should remain closely aligned across UK and international study teams.

4. NIMP classification and safety expectations

The regulation provides additional clarity around non-investigational medicinal products.

For studies involving rescue medication, background therapy, challenge agents or other non-IMP medicinal products, sponsors should review whether these products are correctly classified and whether the protocol, safety management plan and supporting documentation reflect the updated expectations.

5. Urgent Safety Measures

Urgent Safety Measures remain a critical area of sponsor oversight.

Although the written notification timeline has changed from 3 to 7 calendar days, this should not be interpreted as a relaxation of safety expectations. Sponsors still need rapid escalation pathways, documented decision-making and clear coordination between clinical, medical, pharmacovigilance and regulatory teams when immediate action is needed to protect participants.

 

Why this matters for sponsors

The operational impact of the amended regulation will often be felt less in one isolated requirement and more in how safety processes connect across functions.

Misalignment between clinical operations, medical monitoring, pharmacovigilance, regulatory affairs and vendors can create avoidable risk, including:

• delayed or inconsistent safety reporting
• unclear expectedness or causality assessment
• incomplete DSUR inputs
• gaps in RSI governance
• inconsistent documentation across study teams
• uncertainty around urgent safety escalation
• unclear ownership between sponsors, CROs, PV providers and local teams

For ongoing UK trials, sponsors should also assess whether the new pharmacovigilance requirements apply immediately or whether transitional arrangements are relevant. Where previous rules may temporarily continue, this should be clearly documented so that teams understand which reporting process applies and when any transition is required.

 

Practical sponsor checklist

 

How PrimeVigilance can support

PrimeVigilance supports sponsors with end-to-end pharmacovigilance expertise across clinical and post-marketing settings, including:

• clinical trial safety reporting
• SUSAR and follow-up reporting support
• medical review
• aggregate reporting and DSUR preparation
• signal management
• regulatory intelligence
• global compliance oversight
• vendor transition and process alignment
• local and global pharmacovigilance operations

As the UK clinical trials framework moves into its amended regulatory environment, sponsors need more than awareness of the new rules. They need practical alignment across processes, systems, documentation and delivery teams.

PrimeVigilance can help sponsors assess the impact of the amended UK Clinical Trials Regulation on their clinical safety operations and strengthen readiness across ongoing and upcoming UK studies.